Polar Asset Management Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Polar Asset Management Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-433,900	Closed	-$746K	–	748
2025 Q2	$746K	Buy	+433,900	New	+$1.08M	0.01%	395
2024 Q1	–	Sell	-138,000	Closed	-$1.12M	–	830
2023 Q4	$1.12M	Sell	138,000 -85,900	-38%	-$449K	0.02%	415
2023 Q3	$1.02M	Sell	223,900 -172,800	-44%	-$1.13M	0.02%	461
2023 Q2	$2.79M	Buy	+396,700	New	+$2.84M	0.05%	412

Other funds holding IOVA

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Polar Asset Management Partners's IOVA Position: Q3 2025 in Review

Polar Asset Management Partners sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 433,900 shares — an estimated $746K sold.

Polar Asset Management Partners first reported a position in IOVA in Q2 2023 and held it in 4 quarters. The position peaked at $2.79M in Q2 2023. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

Polar Asset Management Partners reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
Polar Asset Management Partners sold 433,900 Iovance Biotherapeutics shares in Q3 2025, an estimated $746K.
Polar Asset Management Partners first reported a position in Iovance Biotherapeutics in Q2 2023 and held it in 4 quarters.
Polar Asset Management Partners's Iovance Biotherapeutics position peaked at $2.79M in Q2 2023.
253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Polar Asset Management Partners's 13F filing for Q3 2025, filed 14 Nov 2025.